UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/524,520	10/31/2005	Hans Loibner	4518-0108PUS1	3426
	7590 01/06/200 ART KOLASCH & BI	EXAMINER		
PO BOX 747	OH MA 22040 0747	DUFFY, BRADLEY		
FALLS CHURCH, VA 22040-0747			ART UNIT	PAPER NUMBER
		1643		
			NOTIFICATION DATE	DELIVERY MODE
			01/06/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/524,520	LOIBNER ET AL.	
Examiner	Art Unit	
BRADLEY DUFFY	1643	

	BRADLEY DUFFY	1643	
The MAILING DATE of this communication appe	ears on the cover sheet with the	correspondence add	ress
THE REPLY FILED <u>15 December 2008</u> FAILS TO PLACE THIS			
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Application (RCE) in compliance with 37 Comperiods:	the same day as filing a Notice of replies: (1) an amendment, affidavieal (with appeal fee) in compliance	Appeal. To avoid abar it, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires <u>3</u> months from the mailing date	of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire Is Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07)	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	g date of the final rejection	n.
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of ex under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	tension and the corresponding amount shortened statutory period for reply origi than three months after the mailing dat	of the fee. The appropria inally set in the final Offic	ate extension fee e action; or (2) as
2. The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any extending Notice of Appeal has been filed, any reply must be filed water MAMENDMENTS.	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. The proposed amendment(s) filed after a final rejection,	out prior to the date of filing a brief	will not be entered be	cause
(a) $oxtime \square$ They raise new issues that would require further co	nsideration and/or search (see NO		cause
(b) They raise the issue of new matter (see NOTE belo		-1i	
 (c) ☐ They are not deemed to place the application in bet appeal; and/or 	ter form for appeal by materially red	aucing or simplifying ti	ne issues for
(d) ☐ They present additional claims without canceling a	corresponding number of finally reig	ected claims	
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.1		solod claimic.	
4. The amendments are not in compliance with 37 CFR 1.12		mpliant Amendment (I	PTOL-324)
5. Applicant's reply has overcome the following rejection(s)		mphane / monamone (i	102 02 1).
6. Newly proposed or amended claim(s) would be al		timely filed amendmer	nt canceling the
non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is provided the status of the claim(s) is (or will be) as follows:		ll be entered and an e	xplanation of
Claim(s) allowed:			
Claim(s) objected to:			
Claim(s) rejected: <u>49</u> . Claim(s) withdrawn from consideration: <u>1-5,7-10,12-15,17</u>	7 22 25 27 20 32 34 43 and 46 48		
AFFIDAVIT OR OTHER EVIDENCE	-22,23-21,29-32,34-43 and 40-40.		
 The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 			
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to of showing a good and sufficient reasons why it is necessary 	vercome <u>all</u> rejections under appear and was not earlier presented. Se	al and/or appellant fails ee 37 CFR 41.33(d)(1)	s to provide a).
10. ☐ The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	ntry is below or attach	ed.
11. The request for reconsideration has been considered bu See Continuation Sheet.	t does NOT place the application in	n condition for allowan	ce because:
12. Note the attached Information <i>Disclosure Statement</i> (s).	(PTO/SB/08) Paper No(s)		
	/Stephen L. Rawlings/ Primary Examiner, Art U	Init 1643	

Continuation of 3. NOTE: Entry of the proposed amendment would raise new issues that would require further consideration because, if entered, e.g., claim 49 would be amended to strike the recitation of "immunocomplexing of tumor cells within the scope of the surgical intervention inhibits dissemination of tumor cells"; while continuing to refer to an immunocomplexing step in a wherein clause. This amendment would raise new issues, e.g., under 35 U.S.C. §112, second paragraph and/or 35 U.S.C. §112, first paragraph; and more particularly it is noted, e.g., that the metes and bounds of the subject matter that is regarded as the invention of the amended claim cannot be determined because the immunocomplexing referred to in the wherein clause lacks antecedent basis in the process step. Therefore, it cannot be determined which (if any) immunocomplexing step is being referred to in the wherein clause. Furthermore, because the wherein clause recites immunocomplexing, but the process steps do not refer to an immunocomplexing step, the claim is indefinite for omitting an essential step. Accordingly, if entered, the claim would fail to delineate the metes and bounds of the subject matter regarded as the invention with the clarity and particularity necessary to satisfy the requirement set forth under 35 U.S.C. § 112, second paragraph, so as to permit the skilled artisan to know or determine infringing subject matter. For theses reasons, entry of the proposed amendment would raise new issues that would require further search and/or consideration. Accordingly, the amendment is not deemed to place this application in better form for appeal by materially reducing or simplifying the issues for appeal.

Continuation of 11. does NOT place the application in condition for allowance because: The request for reconsideration is predicated upon entry of the proposed amendment, and as the amendment has not been entered, Applicant's request is presently moot.